Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
about
Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASColorectal cancer tumour markers and biomarkers: Recent therapeutic advancesNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesNew therapeutic strategies for BRAF mutant colorectal cancersA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisMolecular profiling in the treatment of colorectal cancer: focus on regorafenibPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Personalized treatment for advanced colorectal cancer: KRAS and beyondToward a Molecular Classification of Colorectal Cancer: The Role of BRAFMolecularly targeted drugs for metastatic colorectal cancerRecent applications of chemosensitivity tests for colorectal cancer treatmentCancer concepts and principles: primer for the interventional oncologist-part IIPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesHow to select the optimal treatment for first line metastatic colorectal cancerMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerIdentification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new eraKRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveRAS and BRAF in metastatic colorectal cancer managementEvaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal CancerMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerStandard chemotherapy with cetuximab for treatment of colorectal cancerColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachOverall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.Translating genomic profiling to gastrointestinal cancer treatment.Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available dataRAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.
P2860
Q26738655-C6E1C994-07BB-4D28-B539-580506C39C69Q26740067-4A12A848-632A-47E7-BC32-47283622A32CQ26751035-179AC531-2213-42E7-A958-66CDCF0A705FQ26751344-BDC830D3-60EF-4139-AE2D-A5519B98A950Q26766535-7DB2D2CB-F618-4FA9-9714-AB09EF4E722BQ26768427-03DA0519-53E4-491A-9B48-D8378B347EF0Q26769884-0DA09166-6A86-4ABA-A7FC-009D923988C7Q26772276-A359FAC2-03CF-40D4-B0F4-EDE396AF8344Q26772277-7117C1A6-2950-4DA2-BBAA-E0CC5E726E07Q26775711-5E4AC416-8E3F-4C85-BF46-EDC602E015ACQ26777704-9A8C3AF7-1794-4E47-849D-7B3D8BBB0A36Q26778296-E2268FCC-B100-48DC-8D76-28874F88D487Q26795558-DF020B1F-914B-4297-82A0-6531F286CEC7Q26796348-F6814A33-B644-46A0-8C49-D9009B5CEFBEQ26822817-3FDF387F-C397-473F-9158-4E974DCBCE22Q26827212-305F12B6-1CD6-4D98-B767-2FC9CDC8DA3DQ26828735-BC254EAA-6A2D-41AF-B14C-E5F6C9EF96DBQ26851075-3012861C-8322-46AA-B42C-C381BC6B7D89Q27010961-CBD9F063-A7F5-48A1-A6F7-40798FB5D2DBQ27015224-D7A9B567-7EA8-49CB-9B55-B0774667B5FDQ27026516-1CB9607E-E0BC-448C-B2D3-EE68E74414E1Q27027648-47390402-B146-41F6-AF35-AD92E6AC4641Q27693248-FCB13E0E-29E7-4BF7-97E2-F3B6791E9A6FQ27852414-88488A94-AF2E-402A-9AB0-0A13C014F8FDQ27852988-F1676C4F-8F55-4A96-854A-ABD49E7433E9Q27853121-46FA6D18-71CD-47D8-85FB-A3BE904992FBQ27853216-22547ACA-586C-4B68-B94A-0A08947D97C7Q28070038-123A5B24-A365-4FAE-B022-E8251DEB53E5Q28074175-980056DC-E3CB-4536-8209-4351DF7D6DDDQ28074285-AC723AA3-A3C0-4BB4-B39C-118BC548ED7CQ28076490-F81A16D6-48B9-47DD-B491-A925C957565BQ28088693-BAB9B70C-09FA-481C-9721-461B3F65239EQ28647615-F3628ECB-9BD3-40BB-9B20-3D466DDBA754Q30235144-02A36A50-EFAB-407B-AC5A-4A5C892DC2CCQ30239109-803D2216-F22F-407D-99C5-F1DB7AEA5B8BQ30862367-676ABF25-444A-4FAD-9A16-CC1F97C6DEBDQ30967175-7876362D-ED62-4F6A-A045-682EA2CAB949Q31168985-3A82A89D-C753-4A6E-9D01-9EB2BB0B7F6DQ33555345-79EF52ED-CD7D-4D66-85B3-33A3396E0A71Q33580500-C2AD32F0-B925-4B70-BF7C-8289EDBEFCE7
P2860
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Addition of cetuximab to chemo ...... US randomised clinical trials.
@ast
Addition of cetuximab to chemo ...... US randomised clinical trials.
@en
Addition of cetuximab to chemo ...... US randomised clinical trials.
@nl
type
label
Addition of cetuximab to chemo ...... US randomised clinical trials.
@ast
Addition of cetuximab to chemo ...... US randomised clinical trials.
@en
Addition of cetuximab to chemo ...... US randomised clinical trials.
@nl
prefLabel
Addition of cetuximab to chemo ...... US randomised clinical trials.
@ast
Addition of cetuximab to chemo ...... US randomised clinical trials.
@en
Addition of cetuximab to chemo ...... US randomised clinical trials.
@nl
P2093
P50
P921
P1476
Addition of cetuximab to chemo ...... US randomised clinical trials.
@en
P2093
Carsten Bokemeyer
Ilhan Celik
Michael Schlichting
Philippe Rougier
Steffen Heeger
P304
P356
10.1016/J.EJCA.2012.02.057
P577
2012-03-23T00:00:00Z